Optical Detection of Intravenous Infiltration

在美国，约80%的住院患者需要IV治疗，约50%的IV管线由于以下原因而失败： 渗透、套管中的凝块、静脉的炎症反应或套管与导管的分离。 静脉IV浸润通常伴有插管头端或导管周围的疼痛、红斑和/或肿胀。 插入位点。严重浸润可能导致坏死，需要进行皮肤清创、植皮或 截肢一个常见的领域的医疗事故诉讼提出对医生和护士涉及 浸润细胞毒性药物、静脉营养、钙、钾溶液和 碳酸氢盐，甚至10%的葡萄糖外的静脉，他们被传递到已知的引起皮肤 坏死并在关节周围形成明显的瘢痕。早期发现渗透可防止 发生可能需要手术矫正的严重事件。该项目的长期目标是 提供一种准确、可靠和低成本的工具，可以客观评估IV渗透。 竞争性继续努力的具体目标是：改进IV渗透检测装置， 进行临床试验，并向美国食品和药物管理局提交510（k）申请。

In the United States, about 80% of hospital patients require IV therapy and about 50% of IV lines fail due to infiltration, a clot in the cannula, an inflammatory response of the vein, or separation of the cannula from the vein. IV infiltration is usually accompanied by pain, erythema, and/or swelling at the cannula tip or the insertion site. Severe infiltration may lead to necrosis requiring skin debridement, skin grafting, or amputation. One common area of malpractice lawsuits filed against physicians and nurses involves infiltration. The leakage of cytotoxic drugs, intravenous nutrition, solutions of calcium, potassium, and bicarbonate, and even 10% dextrose outside the vein into which they are delivered is known to cause skin necrosis and to precipitate significant scarring around joints. Early detection of infiltration prevents the occurrence of serious incidents that may require surgical correction. The long-term objective of the project is to provide an accurate, reliable, and low-cost tool that allows objective assessment of IV infiltrations. Specific aims of the Competing Continuation effort are: to refine the IV infiltration detection device, to conduct a clinical trial, and to submit a 510 (k) application to the U.S. Food and Drug Administration.